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Abstract 
We investigated the formation of F&soprostanes produced by non-enzymatic peroxidation of arachidonic acid during rabbit aortic endothelial 
cell-mediated oxidation of low density lipoprotein (LDL). Free and total (sum of free and esteritied) levels of F,-isoprostanes were measured using 
a solid-phase xtraction procedure and gas chromatography-mass pectrometry. Free levels of F,-isoprostanes in native LDL were 0.06 -+ 0.03 ng/mg 
protein (n = 4), whereas total levels were 0.28 + 0.09 ng/mg protein (n = 4). Both free and total levels of the isoprostanes were found to increase during 
the oxidation. I-epi-PGF, was the major isoprostane formed (free and total concentrations after 24 h, 2.50 + 0.24 and 6.42 k 1.36 ng/mg protein 
(n = 4), respectively). The release of F,-isoprostanes during aortic endothelial cell-induced oxidation of LDL could be a contributory factor in the 
development of atherosclerosis. 
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1. Introduction 
Free radical-mediated oxidation of low density lipo- 
protein (LDL) is an important factor in the development 
of atherosclerosis. It has been shown that several cell 
types of the vascular system (endothelial cells, smooth 
muscle cells, fibroblasts, monocytes and macrophages) 
can oxidise LDL in culture [l-4]. It is also known that 
a number of oxidative mechanisms cause native LDL to 
become minimally modified in vivo [5-71. The appear- 
ance of oxidised LDL in the sub-endothelial space of the 
arterial wall is accompanied by the generation of chemo- 
tactic factors. These in turn, initiate a cascade of events 
leading to the formation of fatty streaks which character- 
ise early atherosclerotic lesions. 
In the presence of endothelial cells, smooth muscle 
cells or macrophages, the oxidation of LDL is believed 
to proceed via three major mechanisms which probably 
operate simultaneously [8]. These cells can catalyse the 
oxidative process by: (i) producing and subsequently re- 
leasing highly active oxygen species into the immediate 
environment (superoxide or hydrogen peroxide); (ii) gen- 
erating lipid peroxides, which are then transferred to the 
LDL; and (iii) releasing enzymes which act directly on 
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lipid molecules. Cellular sources of reactive oxygen spe- 
cies and enzymes responsible for catalysing lipid peroxi- 
dation include xanthine oxidase, NADPH, mitochon- 
drial electron transport systems, cyclooxygenase and 
lipoxygenase. Additional non-enzymatic systems which 
can enhance LDL oxidation have also been shown to 
occur in cells [9]. 
At several stages of the oxidation of LDL, the forma- 
tion or depletion of certain molecules can be monitored 
and used as indices of lipid peroxidation. For routine 
biochemical analysis, the formation of conjugated di- 
enes, lipid hydroperoxides, thiobarbituric acid reactive 
substances (TBARS) or the depletion of polyunsaturated 
fatty acids and vitamin E is measured [lo]. Of these, the 
TBARS assay is the most frequently used because of its 
simplicity. This assay is also the most criticised one be- 
cause of its lack of specificity, 
Recently, it has been shown that a series of prosta- 
glandin F,-like compounds (F,-isoprostanes) are pro- 
duced in vivo by free radical-catalysed peroxidation of 
arachidonic acid independent of the cyclooxygenase n- 
zyme [l 11. Of these, 8-epi-PGF, was found to be the 
major product and was shown to be a potent renal and 
pulmonary vasoconstrictor [l l-131. 
We have developed a new method based on a solid- 
phase extraction procedure and GC-MS for the isolation 
and quantitation of F,-isoprostanes in biological fluids 
[14]. This method was applied to monitor the formation 
of F,-isoprostanes during metal-catalysed oxidation of 
LDL [ 151. In this study, we investigated the formation of 
F,-isoprostanes during cell-mediated LDL oxidation 
and examined the possibility of using the formation of 
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%epi-PGF,, as a specific marker of non-enzymatic lipid 
peroxidation. In addition, the quantitative relation be- 
tween F,-isoprostanes, hydroperoxides, conjugated di- 
enes and TBARS is examined. 
2. Materials and methods 
2.1. Materials 
Chemicals were obtained from Sigma Chemical Co. (Poole, UK) or 
Aldrich Chemical Co. (Gillingham, UK). BSTFA (N,O-bis(tri- 
methylsilyl)-trifluoroacetamide) was obtained from Pierce and War- 
riner (Chester, UK). Prostaglandin standards 8-epi-PGF,, 9p.l la- 
PGF,, 9a,ll/?-PGF,, 9a,lla-PGF, and the deuterated analogue of 
9a,l la-PGF, (PGF,-3,3’,4,4’-d,) were purchased from Cascade Bio- 
them Ltd (Reading, UK). Solvents were obtained from Rathbum 
Chemicals Ltd (Walkerburn, UK). 
2.2. Blood collection and isolation of LDL 
Blood (100 ml per donor) was collected in flasks containing 3.8% 
trisodium citrate (blood/anticoagulant ratio of 9 : l), indomethacin (14 
PM) as cyclooxygenase inhibitor and BHT (20 PM) as free radical 
scavenger. Platelet-poor plasma was obtained by centrifugation at 
2400 x g for 15 min at 4°C. LDL was isolated by sequential density 
ultracentrifugation @ = 1.019-l .063) in EDTA (final concentration 
5 mM), using the method of Have1 et al. [16]. The LDL was dialysed 
extensively against 150 mM sodium chloride containing 0.01% EDTA 
(pH 7.4) at 4°C. Protein was determined by the Lowry method using 
bovine serum albumin as a standard [17]. 
2.3. Cells 
Rabbit aortic endothelial cells were used from a line established and 
characterised by Buonassisi et al. [18]. The cells were grown in Ham’s 
F-10 medium containing 15% fetal bovine serum, epidermal growth 
factor (50 ng/ml), endothelial cell growth supplement (75 @ml) and 
heparin (20 ,@ml). Six-well culture plates were seeded with approxi- 
mately 10’ cells and were used at confluence. 
2.4. Oxidation of LDL 
LDL (2OOpg protein/ml) was incubated with washed endothelial cells 
in 1 ml Ham’s F-10 (with glutamine, without Phenol red) at 37°C in 
a humidified 5% CO* atmosphere. Samples were collected at times 0, 
3, 6, 8 and 24 h and stored at 4°C in the presence of BHT (final 
concentration 20 PM) until analysis. Control plates were incubated 
under identical conditions without LDL. 
2.5. Cell viability tests 
Cell viability was determined by microscopic observation and cell 
protein measurements (Lowry method) of the endothelial cells before 
and after the 24 h incubation period. 
2.6. Isolation of F,-isoprostanes 
F,-isoprostanes were isolated using solid-phase xtraction (SPE) [14]. 
For the determination of free levels, LDL (100 pg protein) was spiked 
with the internal standard PGF,-d, (5 ng in 100~1 ethanol). The sample 
was acidified @H 3) and was loaded on a C,, cartridge (Waters). After 
washing sequentially with 10 ml of water (PH 3) and acetonitrile/water 
(15: 85), F,-isoprostanes were eluted with 5 ml of hexanelethyl acetate/ 
propan-2-01 (30: 65 : 5). This eluate was then applied to an NH, car- 
tridge (Supelco). The cartridge was sequentially washed with 10 ml of 
hexanelethyl acetate (30: 70), acetonitrile/water (90: 10) and acetoni- 
trile. F,-isoprostanes were then eluted with 5 ml of methanol/acetic 
acid/ethyl acetate (85: 5: 10). For the analysis of total (sum of free and 
esterified) F,-isoprostanes, 1OOpg of each sample were hydrolysed with 
potassium hydroxide (1.0 M) for 30 min at 40°C prior to the SPE 
procedure. 
2.7. Derivatisation 
F,-isoprostanes collected in the final eluate from the NH, cartridge 
were derivatised to PFB esters and TMS ethers prior to GC-MS anal- 
ysis, as described earlier [15]. 
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2.8. GC-MS analysis 
Samples were analysed on a Hewlett-Packard 5890 GC (Bracknell, 
UK) linked to a VG70SEQ MS (Fisons Instruments, Manchester, UK), 
using electron capture negative ion chemical ionisation (NICI) with 
ammonia reagent gas. F,-isoprostanes were separated with an SPB- 
1701 column (30 m x 0.25 mm ID x 0.25 mm D,, Supelco, PA, USA). 
Quantitative analysis was carried out by selected ion monitoring (SIM) 
of the carboxylate anion [M-181]- at m/z 569 and 573 for the F,-iso- 
prostanes and PGFti-d4, respectively [I51. 
2.9. Additional lipid peroxidation measurements 
Conjugated dienes were detected by spectrophotometry at 234 nm 
[19]. Hydroperoxides were measured using the FOX 2 assay at 560 nm 
[20] and TBARS were monitored at 532 nm [20]. Vitamin E was analy 
sed using HPLC and fluorescence detection as described earlier [15]. 
3. Results 
3.1. Measurement of F,-isoprostanes 
Fig. IA shows a SIM/NICI chromatogram (m/z 569) 
of a mixture of authentic standards following solid-phase 
extraction on C,, and NH, cartridges. A SIM/NICI 
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Fig. 1. GC-MSJNICI selected ion monitoring chromatograms of (A) a 
mixture of authentic PGFr standards, and (B) PGFz compounds iso- 
lated from cell-mediated oxidised LDL. Peaks: (a) SD, lla-PGF,, 
(b) 8-epi-PGF,,, (c) 9a, 1 la-PGF, and (d) 9a, 1 la-PGF,. LDL (200 pg 
protein/ml) was incubated with rabbit aortic endothelial cells in Ham’s 
F-19 at 37°C for 24 h. PGF, compounds were isolated by solid-phase 
extraction and were separated as PFB-ester, TMS-ether derivatives 
using an SPB-1701 column (30 m x 0.25 mm ID x 0.25 pm D,) as 
described in section 2. 
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chromatogram of total (sum of free and esterified) 
F,-isoprostanes isolated by SPE following oxidation of 
LDL by rabbit aortic endothelial cells for 24 h is shown 
in Fig. 1 B. Analysis of native LDL revealed the presence 
of low levels of free F,-isoprostanes (0.06 a 0.03 ng/mg 
protein, n = 4). Total (sum of free and esterified) F,- 
isoprostanes were 0.28 f 0.09 ng/mg protein (n = 4). Of 
these, 8-epi-PGF, was present in abundance. These 
findings suggest hat F,-isoprostanes are present mainly 
in an esterified form in circulating lipoproteins. 
In the presence of endothelial cells, no changes in the 
free and total levels of F,-isoprostanes were observed 
during the first 3 h of incubation. The levels then in- 
creased rapidly during the remaining time of the incuba- 
tion. At t = 24 h, free and total levels of 8-epi- 
PGFzD were 2.50 + 0.24 and 6.42 f 1.36 nglmg 
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Fig. 2. Time course for the formation of (A) and (B) total (sum of free 
and esterified) I-epi-PGF, during cell-mediated oxidaztion of LDL. 
(0) osidised LDL, (*) control. LDL (2OOpg protein/ml) was incubated 
with rabbit aortic endothelial cells in Ham’s F-10 at 37°C for 24 h. 
8-epi-PGF, was isolated by a solid-phase xtraction procedure and was 
analysed by GC-MSMICI as described in section 2. For tota measure- 
ments, the samples were hydrolysed with KOH (1 .O M prior to solid- 
phase extraction. Data points are represented as the mean 5 SD. 
(n = 4). 
protein (n = 4), respectively. Fig. 2 illustrates the time 
course for the formation of free and total 8-epi-PGF, 
during cell-mediated oxidation of LDL. 
In controls (cells alone), 8-epi-PGF,(free or total) 
was not formed during the incubation. In additional con- 
trols (LDL in Ham’s F-10 alone), the initial free 8-epi- 
PGF, levels remained unchanged after 24 h (Fig. 2A) 
whereas the total levels increased by 37.5% (Fig. 2B). 
3.2. Additional lipid peroxidation measurements 
No significant changes in the levels of conjugated di- 
enes, lipid hydroperoxides and TBARS were observed 
during the first 3 h of oxidation. Conjugated dienes in- 
creased uring the following 5 h of incubation (197 + 39.6 
nmol/mg protein at t = 8 h), then decreased gradually 
(Fig. 3). Lipid hydroperoxides (117 f 14.2 nmol/mg pro- 
tein at t = 0) were also found to increase to a maximum 
at t = 8 h, before decreasing (Fig. 3). TBARS reached a 
maximum of 38.3 + 3.1 nmol/mg protein after 24 h (Fig. 
3). Vitamin E (1800 2 79.2 ng/mg protein at t = 0) was 
depleted within the first 6 h of the oxidation reaction. In 
controls, no significant changes were observed in these 
parameters during the incubation period. 
3.3. Cell viability tests 
Cell protein decreased by 7.8% after the 24 h incuba- 
tion, indicating that the oxidation products generated 
were not exerting significant cytotoxicity. No significant 
morphological changes were apparent from microscopic 
observations of the cells. 
4. Discussion 
Recently, we reported the formation of F,-isoprosta- 
nes during copper-mediated LDL oxidation [15]. It was 
found that native LDL contains significant amounts of 
F,-isoprostanes in an esterified form and that their levels 
increase during metal-catalysed oxidation. We also 
found that 8-epi-PGF, was the most abundant iso- 
prostane formed. The increase in free levels of 8-epi- 
PGF, was preceded by an increase in esterified levels. 
Previous studies have shown that rabbit aortic endothe- 
lial cells can oxidise LDL [21,22]. In this study, we inves- 
tigated the formation of FJsoprostanes during cell-me- 
diated LDL oxidation and also examined the possibility 
that the formation of 8-epi-PGF,, may be monitored and 
used as an additional index of the peroxidative process. 
Our results show that 8-epi-PGF, was formed in sub- 
stantial amounts during endothelial cell-induced oxida- 
tion of LDL in vitro (Fig. 1). Both free and total levels 
increased during the 24 h incubation and the final con- 
centrations of total 8-epi-PGF, were about 2.5 times 
higher than the corresponding free levels (Fig. 2). The 
oxidation exhibited a lag phase of about 3 h, during 
which there were no significant changes in the levels of 
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Fig. 3. Formation of (m) lipid hydroperoxides, (+) TBARS and (A) 
conjugated ienes during cell-mediated LDL oxidation. LDL (200 pg 
protein/ml) was incubated with rabbit aortic endothelial cells in Ham’s 
F-10 at 37°C for 24 h. Hydroperoxides, TBARS and conjugated ienes 
were determined by UV/visible spectrophotometry as described in sec- 
tion 2. 
8-epi-PGF, (free and total) as well as lipid hydroperox- 
ides, conjugated dienes and TBARS (Figs. 2 and 3). 
Increased concentrations were found after the lag phase, 
which corresponded to a 47.8% decrease in endogenous 
vitamin E (939 + 21.5 ng/mg protein at t = 3 h). Changes 
in the levels of 8-epi-PGF,, were related to other indices 
of lipid peroxidation showing that its formation can be 
used as an additional index of lipid peroxidation. In 
contrast to copper-mediated LDL oxidation, we also 
found an increase in the formation of a component with 
similar retention time to the cyclooxygenase-derived pro- 
staglandin 9a, 1 la-PGF, (total concentrations of 
0.39 k 0.04 and 10.6 + 2.9 ng/mg protein (n = 4) at t = 0 
and 24 h, respectively). 
These results contribute to growing evidence that en- 
dothelial cells have the capacity to oxidise LDL by sev- 
eral mechanisms operating simultaneously and can gen- 
erate a wide array of compounds, including some which 
are potent pharmacological mediators. Aortic endothe- 
lial cell-induced LDL oxidation could therefore contrib- 
ute to the pathophysiology of atherosclerosis and other 
disease states where considerable oxidative stress may be 
involved. 
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